Key facts
- BeeCure’s last known valuation is $24.0M (Jan 2022).
- It has raised $2.5M; the latest was Later Stage VC ($250K) in Mar 2025.
- Notable investors include Legend Capital, Capital Q Ventures, Evan Greenberg.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BeeCure
- ·The full record, as it builds
Funding rounds
No funding rounds for BeeCure are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BeeCure
Manufacturer of skin care products intended to support recovery following radiation and laser procedures. The company's product features a formulation with buckwheat honey for moisture retention, calendula extract to help minimize inflammation, and bisabolol to promote soothing effects, enabling individuals undergoing treatment to maintain skin integrity and reduce discomfort.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Hollywood, FL, United States
- Founded
- 2016
- Employees
- 3
- Website
- beecure.com/
- Ownership
- Privately Held (backing)
BeeCure doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BeeCure shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BeeCure in its N-PORT filings yet. We sweep new filings monthly.